ArticleFrontiers in microbiology2025
Incidence and risk factors of active carbapenem-resistant enterobacteriaceae surveillance in hematology patients: a propensity score matching study.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A multidimensional nomogram for clinical risk stratification of bloodstream infection and mortality in hematologic malignancies.Frontiers in cellular and infection microbiology · 2026Article
- Risk Factor Analysis of CRE Infections at Different Anatomical Sites in ICU Patients.Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Carbapenem-resistant Enterobacteriaceae (CRE) infections pose a significant threat to hematological patients, contributing to high mortality rates. This retrospective study evaluated the incidence, risk factors, and patient outcomes associated with active CRE surveillance in the hematology department. Methods: The study identified 23,832 hematological patients between 2019 and 2021. Propensity score matching was used to align underlying diseases and admission times in a 1:1:1 ratio across three groups: detected CRE, undetected CRE, and non-active CRE surveillance. The positivity rate of active CRE surveillance was 2.1% (141/6,735), with an incidence of 4.8% (85/1,789) among patients who underwent active CRE surveillance. Results: The distribution of the 141 isolates was as follows: Discussion: The incidence of CRE infection was notably higher in the detected CRE group. Our study provides real-world evidence on the role of active CRE surveillance in survival outcomes, especially in regions like China, where CRE infections are highly prevalent. The findings suggest that active CRE surveillance could serve as an early indicator of 90-day mortality in hematology patients and should be considered for routine implementation in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.